Literature DB >> 19151167

Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia.

Belinda J Schouten1, Matthew P Doogue, Steven G Soule, Penelope J Hunt.   

Abstract

Iron-induced renal phosphate wasting, hypophosphataemia and osteomalacia have previously been reported in a small number of Japanese patients receiving parenteral iron sucrose. We report the case history of a European male who, as a result of regular intravenous iron polymaltose, developed prolonged hypophosphataemia complicated by widespread insufficiency fractures. The pathogenesis of this complication remains unknown however our novel finding of a marked elevation in fibroblast growth factor 23 (FGF23), which normalized after ceasing parenteral iron, suggests an important and previously unreported effect of iron on FGF23 homeostasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151167     DOI: 10.1258/acb.2008.008151

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  36 in total

Review 1.  Recent advances in renal phosphate handling.

Authors:  Emily G Farrow; Kenneth E White
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

2.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.

Authors:  Emily G Farrow; Xijie Yu; Lelia J Summers; Siobhan I Davis; James C Fleet; Matthew R Allen; Alexander G Robling; Keith R Stayrook; Victoria Jideonwo; Martin J Magers; Holly J Garringer; Ruben Vidal; Rebecca J Chan; Charles B Goodwin; Siu L Hui; Munro Peacock; Kenneth E White
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

3.  Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.

Authors:  Erik A Imel; Munro Peacock; Amie K Gray; Leah R Padgett; Siu L Hui; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2011-08-31       Impact factor: 5.958

4.  Approach to the hypophosphatemic patient.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Clin Endocrinol Metab       Date:  2012-03       Impact factor: 5.958

5.  Parenteral iron polymaltose changes i:c-terminal FGF23 ratios in iron deficiency, but not in dialysis patients.

Authors:  S-J Tan; S Satake; E R Smith; N D Toussaint; T D Hewitson; S G Holt
Journal:  Eur J Clin Nutr       Date:  2016-11-16       Impact factor: 4.016

Review 6.  Regulation and function of the FGF23/klotho endocrine pathways.

Authors:  Aline Martin; Valentin David; L Darryl Quarles
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

Review 7.  The changing face of hypophosphatemic disorders in the FGF-23 era.

Authors:  Janet Y Lee; Erik A Imel
Journal:  Pediatr Endocrinol Rev       Date:  2013-06

Review 8.  Fibroblast growth factor 23 and acute kidney injury.

Authors:  Javier A Neyra; Orson W Moe; Ming Chang Hu
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

Review 9.  Fibroblast growth factor 23: state of the field and future directions.

Authors:  Nisan Bhattacharyya; William H Chong; Rachel I Gafni; Michael T Collins
Journal:  Trends Endocrinol Metab       Date:  2012-08-24       Impact factor: 12.015

10.  Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism.

Authors:  Tasuku Saito; Seiji Fukumoto
Journal:  Int J Pediatr Endocrinol       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.